BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mucopolysaccharidosis Type II readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Mucopolysaccharidosis
  Type II\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06075537-10788@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Avlayah (Tividenofusp alfa): Phase 2/3 readout est. (NCT06075537)
DESCRIPTION:Avlayah (Tividenofusp alfa)\, phase 2/3\, Mucopolysaccharidosis
  Type II.\nStudy: An Extension Study of the Long-Term Safety\, Tolerabilit
 y\, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopo
 lysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-00
 07\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06075537
URL:https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05371613-10788@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avlayah (Tividenofusp alfa): Phase 2/3 readout est. (NCT05371613)
DESCRIPTION:Avlayah (Tividenofusp alfa)\, phase 2/3\, Mucopolysaccharidosis
  Type II.\nStudy: A Study to Determine the Efficacy and Safety of Tivideno
 fusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participant
 s With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis 
 Type II (nnMPS II)\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05371613
URL:https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07236606-10822@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Clemidsogene lanparvovec: Phase 3 readout est. (NCT07236606)
DESCRIPTION:Clemidsogene lanparvovec\, phase 3\, Mucopolysaccharidosis Type
  II.\nStudy: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter
  Syndrome)\nEstimated primary completion: 30 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/clemidsogene-lanparvovec#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07236606
URL:https://assetmemo.bio/drug/clemidsogene-lanparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
